Diagnosis and treatment of Paget's disease of bone

Clinical and Investigative Medicine

Volumn 30, Issue 5, 2007, Pages

  Josse, Robert G ^a   Hanley, David A ^b   Kendler, David ^c   Ste Marie, Louis Georges ^d   Adachi, Jonathan D ^e   Brown, Jacques ^f  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Health Sciences Centre Calgary   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ANALGESIC AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CREATININE; ETIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARACETAMOL; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE PAIN; BONE RADIOGRAPHY; CAUCASIAN; FEVER; GEOGRAPHIC DISTRIBUTION; HUMAN; INJECTION SITE PHLEBITIS; OSSIFICATION; OSTEOLYSIS; PAGET BONE DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; SYMPTOM; UNITED KINGDOM;

AGE FACTORS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CANADA; DIPHOSPHONATES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GREAT BRITAIN; GUIDELINES AS TOPIC; HUMANS; MALE; OSTEITIS DEFORMANS; OSTEOGENESIS; PREVALENCE; REMISSION INDUCTION; SEX FACTORS;

EID: 35948946539     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Selby PL, Davie MWJ, Ralston H, et al. Guidelines on the management of Paget's disease of bone. Bone 2002;31:10-9.
2. Cooper C, Harvey NC, Dennison EM, and van Staa TP. Update on the Epidemiology of Paget's Disease of Bone. J Bone Miner Res 2006;21:P3-P8.
3. Boland MJ, Tong PC, Naot D, Callon KE, Wattie DJ, Gamble GD, and Cundy T. Delayed Development of Paget's Disease in Offspring Inheriting SQSTM1 Mutations. J Bone Miner Res 2007;22:411-5.
4. Altman RD. Epidemiology of Paget's disease of bone. Clin Rev Bone Miner Metab 2002;1:99-102.
5. Reddy SV. Aetiology of Paget's disease and osteoclast abnormalities. J Cell Biochem 2004;93:688-96.
6. Selby PL, Davies M, and Mee AP. Canine Distemper Virus Induces Human Osteoclastogenesis Through NF-κB and Sequestosome 1/P62 Activation. J Bone Miner Res 2006;21:1750-6.
7. Roodman GD, Windle JJ. Paget's disease of bone. J Clin Invest 2005;115:200-8.
8. Ralston SH. Pathogenesis of Paget's disease of bone. Clin Rev Bone Miner Metab 2002;1:109-14.
9. Singer FR, Gruber HE, Windle JJ, Roodman GD. Ultrastructure of bone cells in Paget's disease of bone. J Bone Miner Res 2006;21(Suppl 2):P51-P54.
10. Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. J Bone Miner Res 1991;6:495-500.
11. Morales-Piga AA, Rey-Rey JS, Corres-Gonzalez J, Garcia-Sagredo JM, Lopez-Abente G. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 1995;10:663-70.
12. Fotino M, Haymovits A, Falk CT. Evidence for linkage between HLA and Paget's disease. Transplant Proc 1977;9:1867-8.
13. Tilyard MW, Gardner RJ, Milligan L, Cleary TA, Stewart RD. A probable linkage between familial Paget's disease and the HLA loci. Aust N Z J Med 1982;12:498-500.
14. Cody JD, Singer FR, Roodman GD, et al. Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 1997;61:1117-22.
15. Laurin N, Brown JP, Lemainque A, et al. Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 2001;69:528-43.
16. Hocking LJ, Herbert CA, Nicholls RK, et al. 2001 Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet 2001;69:1055-61.
17. Good DA, Busfield F, Fletcher BH, et al. Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet 2002;70:517-25.
18. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002;70:1582-8.
19. Morissette J, Laurin N, Brown JP. Sequestosome 1: Mutation Frequencies, Haplotypes, and Phenotypes in Familial Paget's Disease of Bone. J Bone Miner Res 2006;21:P38-P44.
20. Layfield R, Hocking LJ. SQSTM1 and Paget's disease of bone. Calcif Tissue Int 2004;75:347-57.
21. Kanis JA. Pathophysiology and treatment of Paget's disease of bone. 2nd edition London:Martin Dunitz:110-38,1998.
22. Devogelaer J-P. Modern therapy for Paget's disease of bone. Focus on bisphosphonates. Treat Endocrinol 2002;1:241-57.
23. Drake WM, Kendler DL, Brown JP. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance Symposium. Clin Ther 2001;23(:620-6.
24. Alexandersen P, Peris P, Guanabens N, et al. Non-isomerized c-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 2005;20:588-95.
25. Morris CD, Einhorn TA. Bisphosphonates in orthopedic surgery. J Bone Joint Surg Am 2005;87:1609-18.
26. Melton III LJ, Tiegs RD, Atkinson EJ, O'Fallon WM. Fracture risk among patients with Paget's Disease: A population-based cohort study. J Bone Miner Res 2000;15:2123-8. Abstract available at www.jbmronline.org/doi/abs/10.1359/jbmr. 2000.15.11.2123.
27. Meunier PJ, Vignon E. Therapeutic strategy in Paget's disease of bone. Bone 1999;17(5 suppl):489S-491S.
28. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteo Reports 2003;1:45-52.
29. Shane E, Goldring S, Christakos S et al. Osteonecrosis of the Jaw: More Research Needed. J Bone Miner Res 2006;21:1503-5.
30. Papapoulos SE, Eekhoff EMW, Zwinderman AH. Acquired resistance to bisphosphonates in Paget's disease of bone. J Bone Miner Res 2006;21(suppl 2):88-91.
31. Reid IR, Miller P, Lyles K et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.
32. Hosking D, Lyles K, Brown JP et al. Long-Term Control of Bone Turnover in Paget's Disease with Zoledronic Acid and Risedronate. J Bone Miner Res 2007;22:142-8.
33. Walsh JP, Ward LC, Stewart GO, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 2004;34:747-54.
34. Al M, Groot M, Galani C, Engbersen A. Economic evaluation of long term management strategies for Paget's disease of bone. Abstract SA465. ASBMR 27th Annual Meeting, Nashville, Tennessee 2005.
35. Mittman N, Isogai PK, Adachi JD, Kindunu CM, Barbeau M. Economic evaluation of Aclasta® (zoledronic acid 5 mg) versus Actonel® in treatment of Paget's disease of bone. A Canadian perspective. Poster presentation, March 7, 2006; ECCE 2006, Vienna.